Fewer participants reported one or more confirmed ( 3.9 mmol/L ) or severe nocturnal hypoglycemic events between week 9 and month 6 with Gla-300 ( 36 vs. 46 % with Gla-100 ; relative risk 0.79 [ 95 % CI 0.67-0 .93 ] ; P < 0.005 ) ; nocturnal hypoglycemia incidence and event rates were also lower with Gla-300 in the first 8 weeks of treatment .